Condition (MeSH)
Furunculosis
ClinicalTrials.gov lists 15 trials for Furunculosis or a narrower condition beneath it. AbbVie (prior sponsor, Abbott) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
14 of the 15 trials are tagged with Furunculosis itself; the rest are tagged with a narrower condition beneath it.
When did Furunculosis trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2011 | 3 |
| 2010 | 1 |
| 2009 | 1 |
| 2008 | 2 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 15 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Furunculosis trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 7 |
| Observational | 1 |
How many Furunculosis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 11 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Furunculosis trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AbbVie (prior sponsor, Abbott) | 2 |
| Laboratorios Goulart S.A. | 1 |
Which drugs are being tested for Furunculosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Mupirocin | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 2% Mupirocin Ointment | 2 |
| Adalimumab-US | 2 |
| Vapocoolant | 1 |
| Hydroxychloroquin | 1 |
| 4% Chlorhexidine liquid soap | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Furunculosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| HIDRADENITIS | 14 | 2 |
| ABORTION INDUCED | 2 | 2 |
| ECTOPIC PREGNANCY | 2 | 1 |
| PNEUMONIA | 2 | 2 |
| SUICIDE ATTEMPT | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Furunculosis? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Furunculosis in a high school football team. | The American journal of sports medicine | 1982 | Yes |
| High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. | Annals of emergency medicine | 2005 | No |
| Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. | The Lancet. Infectious diseases | 2005 | No |
| Roentgen therapy for infections: an historical review. | The Yale journal of biology and medicine | 1991 | No |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.